Head and Neck Oncology: Clinical Management

Related Blogs

• Related Blogs on Clinical
• Surprise inspections on Indian clinical trial sites (CROs) from …

• Related Blogs on Head

• Related Blogs on Management

$216.94

Biology and Management of Lung Cancer

Product Description
This volume presents a wide-ranging selection of informative reviews on aspects of the malignant lymphomas, including Hodgkin’s disease. Ten topical essays on issues relevant to the management of patients with malignant lymphomas are presented. Treatment of common lymphomas, such as diffuse large cell lymphoma or Hodgkin’s disease, is considered, as are approaches to unusual problems like CNS lymphoma or immunosuppressive therapy-related lymphoproliferation. Results are presented both from long-term multicenter, Phase III trials and from single-institutions, Phase I studies. The data are discussed by experienced and knowledgeable clinical scientists. Malignant Lymphomas, including Hodgkin’s Disease: Diagnosis, Management, and Special Problems provides an illuminating update for anyone who treats these fascinating diseases.
$97.89

Malignant Lymphomas, including Hodgkin’s Disease: Diagnosis, Management, and Special Problems

Related Blogs

• Related Blogs on Diagnosis

• Related Blogs on Disease

• Related Blogs on Hodgkin’s

Management of Gastric Cancer

Related Blogs

• Related Blogs on CANCER

• Related Blogs on Gastric
• Stomach (Gastric) Cancer – Causes, Signs, Symptoms, Treatment and …
• How Gastric Bypass Surgery is Saving Lives · ArticleMarks

• Related Blogs on Management

Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias

Related Blogs

• Related Blogs on Approaches
• Purgatory Dallas

• Related Blogs on Classification

• Related Blogs on Immunologic
• Free Laptops

Product Description
From a patient’s standpoint, nausea and vomiting constitute two of the most feared adverse effects of cancer therapy. Over the past fifteen years, substantial progress has been made in developing more effective and better-tolerated therapies to prevent treatment-induced nausea and vomiting in cancer patients. This book provides a comprehensive overview of the extent of this problem, the types of nausea and vomiting arising from cancer treatment, a review of pathophysiologic mechanisms and predictive factors and options available for treatment strategies. Despite dramatic therapeutic gains in this area, a substantial minority of patients continues to have inadequately controlled treatment-induced nausea and vomiting. The book introduces readers to promising new antiemetic agents and provides a glimpse into the most promising research avenues of the future. For any cancer professional interested in minimizing treatment-induced complications for their patients, this book provides the most up-to-date overview of the topic currently available.

Management of Nausea and Vomiting in Cancer and Cancer Treatment

Related Blogs

• Related Blogs on CANCER
• Club Pictures

• Related Blogs on Management

• Related Blogs on Nausea

Product Description

Over the last 5 years significant advances have been made in our understanding of the biology of breast cancer. As a result of linking observations made in the laboratory to new treatment strategies, the outcome of breast cancer patients with both early and late stage disease has continued to improve. This volume will highlight many of the important advances that have improved our understanding of the biology and therapeutics of breast cancer.

The initial discussion will focus on the evolving understanding of the genetics of breast cancer. (Olapade or Pasche) In addition to the well known genetic mutations BRCA1 and BRCA2, other mutations that have recently been identified will be discussed. In addition, strategies for surveillance of high-risk populations and prevention strategies under evaluation are highlighted. The underlying molecular pathways that control malignant cell growth are being better characterized thru laboratory investigation and as a result of this work numerous novel therapeutics that target these pathways in already in the clinic to define whether there is clinical benefit in breast cancer patients. Dr Pegram will discuss the rationale for development of some of the agents farthest along in clinical development.

Though novel therapeutic agents or “targeted therapy” hold significant promise, standard treatment modalities including chemotherapy, endocrine therapy, surgery and radiation therapy will remain important for management of breast cancer patients. The decision to offer patients with early stage breast cancer systemic adjuvant therapy has been made based largely on clinical parameters including tumor size and nodal status. Clinicians have long recognized that this method of evaluating risk of recurrence for an individual patient is imprecise. Much research over the last several years has focused on developing molecular profiles of individual tumors that correlate with long-term outcome. Dr. Paik will discuss the development of this strategy and the results of the Oncotype DX Breast Cancer Assay, the first clinically available assay.

In the last 5 years, the aromatase inhibitors have been investigated extensively as an alternative to tamoxifen or as a class of agents that adds to the effects of tamoxifen in postmenopausal woman with hormone receptor positive breast cancer. A review of the data from pivotal trials will be put in context by Dr O’ Regan. Similarly, adjuvant chemotherapy has been refined in recent years to include taxanes and trastuzamab in select patients. Dr. Ravdin will highlight the findings from the most recent (2005) Oxford Overview of randomized clinical trials involving chemotherapy and tamoxifen. Dr Hudis will provide a critical analysis of the how recent data related to the incorporation of taxanes and trastuzamab in adjuvant therapy programs refines clinical decision-making.

Local therapy in the form of radiation and surgery are critical components of the management of breast cancer patients. As more systemic therapy is administered in the preoperative setting, implications for breast conservation and management of the axilla are critical. Dr Newman will review the recent data that is relevant to this topic and Dr Hanson will place in context the role of sentinal lymph node biopsy and the controversies that remain regarding its use in certain situations. Finally Dr Vicini will review the emerging data related to new techniques of breast irradiation and how these potentially more patient “friendly” approaches compare to standard breast irradiation.

Advances in Breast Cancer Management

Related Blogs

• Related Blogs on Advances

• Related Blogs on Breast

• Related Blogs on CANCER
• Grapevine Chill Club

Product Description
This volume outlines patient care from diagnosis through various treatments for thyroid cancer patients. It serves as a state-of-the-art reference for clinicians providing comprehensive information on the scope of this disease, including surgery, nuclear medicine treatments, recurrence and metastases. Reference information is included for both physicians and thyroid cancer patients.

Essentials of Thyroid Cancer Management

Related Blogs

• Related Blogs on CANCER

• Related Blogs on Essentials
• Ypulse Essentials: Chegg Gets Cheeky, Katherine Paterson Named …
• Fix Microsoft Security Essentials (MSE) Not Auto Update Virus and …

• Related Blogs on Management